Apparent inosine uptake by the human heart.
Although inosine has been used clinically to support the myocardium, no data are available on the fate of exogenous inosine in the human heart. We therefore infused six patients, catheterised for coronary angiography, with inosine (5 mg.kg-1.min-1 intravenously) for 6 minutes. Before infusion, the arterio-venous difference of inosine, hypoxanthine and xanthine across the heart was nil. During infusion, arterial inosine increased substantially, exceeding the coronary sinus concentration by a maximum of 200 (SEM 53) mumol.litre-1, p = 0.02, at the fourth minute. Arterial hypoxanthine and xanthine also increased, while the arterio-venous difference became 16(11) and 10(3) (p = 0.04) mumol.litre-1, respectively. Left ventricular dP/dtmax increased by 22(7)% (p = 0.04) at the end of infusion. Thus, there seemed to be substantial uptake of inosine by the human heart, followed by improvement in haemodynamics.
de Jong
J W
JW
Cardiochemical Laboratory, Erasmus University Rotterdam, The Netherlands.
Czarnecki
W
W
Ruzyllo
W
W
Huizer
T
T
Herbaczyńska-Cedro
K
K
D000328:Adult; D006328:Cardiac Catheterization; D003327:Coronary Disease / Q000378:metabolism* / Q000503:physiopathology; D005260:Female; D006439:Hemodynamics; D006801:Humans; D019271:Hypoxanthine; D007042:Hypoxanthines / Q000097:blood; D007288:Inosine / Q000097:blood / Q000493:pharmacokinetics*; D008297:Male; D008875:Middle Aged; D009206:Myocardium / Q000378:metabolism*; D019820:Xanthine; D014970:Xanthines / Q000097:blood
D007042:Hypoxanthines; D014970:Xanthines; D019820:Xanthine; D019271:Hypoxanthine; D007288:Inosine